nach oben

HNO

Erschienen in:

06.04.2016 | Leitthema

Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck

verfasst von: PD Dr. M. Mandapathil

Erschienen in: HNO | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

This review article describes the potential role of ectonucleotidase activity, adenosine metabolism, and the adenosinergic signaling pathway in the suppression of the host immune system in patients with head and neck cancer. Identifying such mechanisms leads to a better understanding of immunosuppressive mechanisms in this patient population. Further, potential targets for immunotherapy in an adjuvant approach to treating squamous cell carcinoma of the head and neck in the future might be identified and improve the prognosis of these patients.

Parkin DM, Bray F, Ferlay J (2005) Pisani P Global cancer statistics. CA Cancer J Clin 55:74–108CrossRefPubMed

Joseph AW, D’Souza G (2012) Epidemiology of human papillomavirus-related head and neck cancer. Otolaryngol Clin North Am 45(4):739–764CrossRefPubMed

Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cacner. N Engl J Med 345:1890–1900CrossRefPubMed

Helmy KY, Patel SA, Nahas GR, Rameshwar P (2013) Cancer immunotherapy: Accomplishments to date and future promise. Ther Deliv 4(10):1307–1320 (Review)CrossRefPubMed

Khaled YS, Ammori BJ, Elkord E (2013) Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 91(8):493–502CrossRefPubMed

Allard B, Turcotte M, Stagg J (2012) CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. Biomed Biotechnol. doi:10.1155/2012/485156

Frumento G, Piazza T, Di Carlo E, Ferrini S (2006) Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6(3):233–237 (Review)CrossRefPubMed

Whiteside TL (2005) Immunobiology of head and neck cancer. Cancer Metastasis Rev 24(1):95–105 (Review)CrossRefPubMed

Stevens AP, Spangler B, Wallner S, Kreutz M, Dettmer K, Oefner PJ, Bosserhoff AK (2009) Direct and tumor microenvironment mediated influences of 5′-deoxy-5′-(methylthio)adenosine on tumor progression of malignant melanoma. J Cell Biochem 106(2):210–219CrossRefPubMed

10.

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLOS ONE 3(7):e2599CrossRefPubMedPubMedCentral

11.

Verrax J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PB (2009) In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem 16(15):1821–1830 (Review)CrossRefPubMed

12.

Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012) CD73: a potent suppressor of antitumor immune responses. Trend Immunol 33(5):231–237CrossRef

13.

Csoka B, Fornai M, Colucci R, Kokai E, Blandizzi C, Hasko G (2014) Adenosine and inflammation: what’s new on the horizon? Drug Discov Today 00072-5(14):1359–6446

14.

Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J (2008) Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol 32(3):527–535 (Review)PubMed

15.

Yang A, Mucsi AD, Desrosiers MD, Chen JF, Schnermann JB, Blackburn MR, Shi Y (2010) Adenosine mediated desensitization of cAMP signaling enhances T‑cell responses. Eur J Immunol 40(2):449–459 (Feb)CrossRefPubMedPubMedCentral

16.

Häusler SF, del Montalbán BI, Strohschein J, Anoop CP, Engel JB, Hönig A, Ossadnik M, Horn E, Fischer B, Krockenberger M, Heuer S, Seida AA, Junker M, Kneitz H, Kloor D, Klotz KN, Dietl J, Wischhusen J (2011) Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2 A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60(10):1405–1418CrossRefPubMed

17.

Antonioli L, Blandizzi C, Pacher P, Immunity HG (2013) inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13(12):842–857CrossRefPubMed

18.

Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M (2012) The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2 A adenosine receptor pathway. Front Immunol 3:190CrossRefPubMedPubMedCentral

19.

Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10(7):490–500CrossRefPubMed

20.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285–1294CrossRefPubMedPubMedCentral

21.

Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303–1310CrossRefPubMedPubMedCentral

22.

Groux H, O’Garra A, Bigler M et al (1997) A CD4+ T‑cell subset inhibits antigen-specific T‑cell responses and prevents colitis. Nature 389:737–742CrossRefPubMed

23.

Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68–79CrossRefPubMed

24.

Jeron A, Pfoertner S, Bruder D, Geffers R, Hammerer P, Hofmann R, Buer J, Schrader AJ (2009) Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. Tumour Biol 30(3):160–170CrossRefPubMed

25.

Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, Ni B, Lu B, Wang H (2014) An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PloS One 9(3):e915544

26.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169(5):2756–2761CrossRefPubMed

27.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell’Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4):1225–1232CrossRefPubMed

28.

Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF et al (1996) Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156:1349–1355PubMed

29.

Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS (2000) The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med 192:1223–1236CrossRefPubMedPubMedCentral

30.

Yang Q, Du J, Zu L (2013) Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol Oncol Res 19(4):811–814CrossRefPubMed

31.

Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P (2008) Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134(3):365–372CrossRefPubMed

32.

Ohta A, Madasu M, Subramanian M, Kini R, Jones G, Choukèr A, Ohta A, Sitkovsky M (2014) Hypoxia-induced and A2 A adenosine receptor-independent T‑cell suppression is short lived and easily reversible. Int Immunol 26(2):83–91CrossRefPubMedPubMedCentral

33.

Varilla V, Atienza J, Dasanu CA (2013) Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 13(9):1241–1256CrossRefPubMed

34.

Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13:32–42CrossRef

35.

Serra A, Horensteil AL, Vaissitti T et al (2011) CD73-generated extracellular adenosine in chronic lymphatic leukemia creates local conditions counteracting drug-induced cell death. Blood 23:6141–6152CrossRef

36.

Rickles RJ, Tam WF, Giordano TP et al (2012) Adenosine A2 A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther 11(7):1432–1442CrossRefPubMed

37.

Leone RD, Lo YC, Powell JD (2015) A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 13:365–372

38.

Michaud M, Martins I, Sukkurwala AQ et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (80- ) 334(6062):1573–1577CrossRef

39.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, Gorelik E, Lang S, Johnson JT, Whiteside TL (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15(20):6348–6357CrossRefPubMedPubMedCentral

40.

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6):1257–1265CrossRefPubMedPubMedCentral

41.

Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285(10):7176–7186CrossRefPubMedPubMedCentral

42.

Mandapathil M, Szczepanski M, Harasymczuk M, Ren J, Cheng D, Jackson EK, Gorelik E, Johnson J, Lang S, Whiteside TL (2012) CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 1(5):659–669CrossRefPubMedPubMedCentral

43.

Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J et al (2011) ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 4:ra12CrossRefPubMed

44.

Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M (2009) A2Aadenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183(9):5487–5494CrossRefPubMed

45.

Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD (2008) A2 A receptor signaling promotes peripheral tolerance by inducing T‑cell anergy and the generaton of adaptive regulatory T cells. Blood 111(1):251–259CrossRefPubMedPubMedCentral

46.

Whiteside TL (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10(7):1019–1035 (Jul)CrossRefPubMedPubMedCentral

47.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH (2009) Sunitinib mediates reversal of myeloid-derived suppressor cells accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148–2157CrossRefPubMed

48.

De Vries IJ, Castelli C, Huygens C, Jacobs JF, Stocki J, Schuler G, Coulie PG, Lucas S (2011) Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 17(4):841–848CrossRefPubMed

49.

Rai AK, Thakur CP, Kumar P, Mitra DK (2012) Impaired expression of CD26 compromises T‑cell recruitment in human visceral leishmaniasis. Eur J Immunol 42(10):2782–2791CrossRefPubMed

Titel: Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck
verfasst von: PD Dr. M. Mandapathil
Publikationsdatum: 06.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: HNO / Ausgabe 5/2016
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-016-0137-7

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Die Bedeutung von MiRNA für das Kopf-Hals-Karzinom

Die neue Krankenhauseinweisungs-Richtlinie

Leitlinie: „HNO-spezifische Therapie der obstruktiven Schlafapnoe bei Erwachsenen“

Schwellungen der Glandulae submandibularis und parotis

Spezifische Anosmie als Prinzip olfaktorischer Wahrnehmung

Preisträger 2015 der Deutschen Gesellschaft für HNO-Heilkunde, Kopf-und Hals-Chirurgie

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO